Aberrantly Glycosylated GLUT1 as a Poor Prognosis Marker in Aggressive Bladder Cancer
International Journal of Molecular Sciences · 19.03.2024 · 25 (6) · 3462
DOI: 10.3390/ijms25063462 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.03.2024. Verfasst von Eduardo Ferreira und 13 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Pathology and Therapeutics Group, Research Center of IPO-Porto (CI-IPOP), 4200-072 Porto, Portugal. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e Tecnologia, PT national funds (FCT/MCTES, Fundação para a Ciência e Tecnologia and Ministério da Ciência, Tecnologia e Ensino Superior), Porto Comprehensive Cancer Center Raquel Seruca.
Abstract (Originalsprache)
Muscle-invasive bladder cancer (MIBC) remains a pressing health concern due to conventional treatment failure and significant molecular heterogeneity, hampering the development of novel targeted therapeutics. In our quest for novel targetable markers, recent glycoproteomics and bioinformatics data have pinpointed (glucose transporter 1) GLUT1 as a potential biomarker due to its increased expression in tumours compared to healthy tissues. This study explores this hypothesis in more detail, with emphasis on GLUT1 glycosylation patterns and cancer specificity. Immunohistochemistry analysis across a diverse set of human bladder tumours representing all disease stages revealed increasing GLUT1 expression with lesion severity, extending to metastasis, while remaining undetectable in healthy urothelium. In line with this, GLUT1 emerged as a marker of reduced overall survival. Revisiting nanoLC-EThcD-MS/MS data targeting immature O-glycosylation on muscle-invasive tumours identified GLUT1 as a carrier of short glycosylation associated with invasive disease. Precise glycosite mapping uncovered significant heterogeneity between patient samples, but also common glycopatterns that could provide the molecular basis for targeted solutions. Immature O-glycosylation conferred cancer specificity to GLUT1, laying the molecular groundwork for enhanced targeted therapeutics in bladder cancer. Future studies should focus on a comprehensive mapping of GLUT1 glycosites for highly specific cancer-targeted therapy development for bladder cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Pathology and Therapeutics Group, Research Center of IPO-Porto (CI-IPOP), 4200-072 Porto, Portugal.
- RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), 4200-072 Porto, Portugal.
- ICBAS-Institute of Biomedical Sciences Abel Salazar, University of Porto, 4050-313 Porto, Portugal.
- i3S-Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal.
- INEB-Institute for Biomedical Engineering, University of Porto, 4200-135 Porto, Portugal.
- REQUIMTE-LAQV, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal.
ORCID-Profile: Dylan Ferreira, Marta Relvas-Santos, Rui Freitas, Janine Soares, Martina Gonçalves, André M N Silva, Andreia Peixoto, José Alexandre Ferreira
Förderung
- Fundação para a Ciência e Tecnologia
- PT national funds (FCT/MCTES, Fundação para a Ciência e Tecnologia and Ministério da Ciência, Tecnologia e Ensino Superior)
- Porto Comprehensive Cancer Center Raquel Seruca
- Norte Portugal Regional Operational Programme (NORTE 2020)
- European Regional Development Fund
- European Social Fund
- Portuguese Oncology Institute of Porto—Research Centre
- Portuguese Foundation for Science and Technology (FCT)
Zitieren
APA
Ferreira, E., Ferreira, D., Relvas-Santos, M., Freitas, R., Soares, J., Azevedo, R., Afonso, L. P., Lima, L., Santos, B., Gonçalves, M., Silva, A. M. N., Santos, L. L., Peixoto, A., & Ferreira, J. A. (2024). Aberrantly Glycosylated GLUT1 as a Poor Prognosis Marker in Aggressive Bladder Cancer. International Journal of Molecular Sciences, 25(6), 3462. https://doi.org/10.3390/ijms25063462
Vancouver
Ferreira E, Ferreira D, Relvas-Santos M, Freitas R, Soares J, Azevedo R, et al. Aberrantly Glycosylated GLUT1 as a Poor Prognosis Marker in Aggressive Bladder Cancer. International Journal of Molecular Sciences. 2024;25(6):3462. doi:10.3390/ijms25063462
BibTeX
@article{Ferreira2024,
author = {Ferreira, Eduardo and Ferreira, Dylan and Relvas-Santos, Marta and Freitas, Rui and Soares, Janine and Azevedo, Rita and Afonso, Luís Pedro and Lima, Luís and Santos, Beatriz and Gonçalves, Martina and Silva, André M N and Santos, Lúcio Lara and Peixoto, Andreia and Ferreira, José Alexandre},
title = {Aberrantly Glycosylated GLUT1 as a Poor Prognosis Marker in Aggressive Bladder Cancer},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {6},
pages = {3462},
doi = {10.3390/ijms25063462}
}
EUVIMED